Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Huperzine A

Drug Profile

Huperzine A

Alternative Names: HupA oral; Huperzine A oral; Qian-ceng-ta

Latest Information Update: 11 Feb 2011

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Chinese Academy of Sciences; Mayo Clinic
  • Developer Chinese Academy of Sciences; Neuro-Hitech
  • Class Alkaloids; Neuroprotectants; Nootropics; Sesquiterpenes
  • Mechanism of Action Acetylcholinesterase inhibitors; Amyloid beta-protein inhibitors; Antioxidants; NMDA receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Marketed Alzheimer's disease

Most Recent Events

  • 10 Feb 2011 Discontinued - Phase-II for Alzheimer's disease in USA (PO)
  • 05 Feb 2008 Interim efficacy data from the double-blind part of a phase II trial in patients with mild-to-moderate Alzheimer's disease released by Neuro-Hitech
  • 15 Dec 2007 Neuro-Hitech completes the double-blind portion of a phase II trial in Alzheimer's disease in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top